VALIDATION OF A PANEL OF BIOMARKERS ASSOCIATED WITH AGGRESSIVE PHENOTYPE OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18513Keywords:
aggressive phenotype, biomarker panels, endometrioid endometrial carcinomaAbstract
Aim: To evaluate the prognostic significance of a panel of biomarkers for the identification of a highly malignant molecular subtype of endometrioid carcinoma of the endometrium (ECE). Materials and Methods: The expression of a number of markers (CD24, CD44, E2F1, FOXP3, Her2/neu, p21WAF1/CIP1, p53, β-catenin, vimentin, Е-cadherin, с-Myc, cyclins D1 and Е1) was determined by the immunohistochemical method in the samples of resected tumors of 127 patients with ECE of I–II stage. The Kullback method and the PanelomiX web tool were used to assess the informativeness and identify the aggressive subtype of ECE. The associative relationships of the studied markers were determined using the STRING v11 database. Results: The study of the prognostic significance of a number of biomarkers in ECE has revealed the informativeness, high specificity and sensitivity (> 95%) of the р53+FOXP3-c-Myc+ phenotype, which is associated with a more aggressive tumor process. Bioinformatics analysis confirmed the correlative relationships between p53, FOXP3 and c-Myc, which are significant prognostic markers associated with cancer progression in ECE patients. Conclusions: The identified molecular phenotype of ECE (р53+FOXP3-c-Myc+) has differential and prognostic significance and objectively reflects a highly malignant subtype of this form of cancer.
References
World Health Organization. GLOBOCAN 2018: Estimated cancer incidence, mortality and prevalence worldwide in 2018. 2018; Available: http://gco.iarc.fr/today/ data/factsheets/cancers/24-Corpus-uteri-fact-sheet.pdf
Fedorenko Z, Michailovich Yu, Goulak L, et al. Cancer in Ukraine, 2019-2020: Incidence, mortality, prevalence and other relevant statistics Bulletin of the National Cancer Registry of Ukraine 2021; 22: 84 p.
Hu S, Hinson JL, Matnani R, et al. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma. Mod Pathol 2018; 31: 358–64. https://doi.org/10.1038/modpathol.2017.131
Salama A, Arafa M, ElZahaf E, et al. Potential role for a panel of immunohistochemical markers in the management of endometrial carcinoma. J Pathol Transl Med 2019; 53: 164–72. https://doi.org/10.4132/jptm.2019.02.12
Soslow RA, Tornos C, Park KJ, et al. Еndometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol 2019; 38: S64–74. https://doi.org/10.1097/PGP.0000000000000518
Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer 2019; 19: 510–21. https://doi.org/10.1038/s41568-019-0177-x
Njoku K, Chiasserini D, Whetton AD, Crosbie EJ. Proteomic biomarkers for the detection of endometrial cancer. Cancers (Basel) 2019; 11: 1572. https://doi.org/10.3390/cancers11101572
Murali R, Davidson B, Fadare O, et al. High-grade еndometrial сarcinomas: morphologic and іmmunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol 2019; 38: S40–63. https://doi.org/10.1097/PGP.0000000000000491
Salinas EA, Miller MD, Newtson AM, et al. A prediction model for preoperative risk assessment in endometrial cancer utilizing clinical and molecular variables. Int J Mol Sci 2019; 20: 1205. https://doi.org/10.3390/ijms20051205
McDermott JE, Jing W, Hugh M, et al. Challenges in biomarker discovery: combining expert insights with statistical analysis of complex omics data. Expert Opin Med Diagn 2013; 7: 37–51. https://doi.org/10.1517/17530059.2012.718329
Jiang Z, Song Y, Shou Q, et al. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables. Trials 2014; 15: 500. doi.org/10.1186/1745-6215-15-500. https://doi.org/10.1186/ 1745-6215-15-500
Gola D, Mahachie John JM, van Steen K, König IR. A roadmap to multifactor dimensionality reduction methods. Brief Bioinform 2016; 17: 293–308. https://doi.org/10.1093/bib/bbv038
Robin X. PanelomiX for the combination of biomarkers. Methods Mol Biol 2019; 1959: 261–73. https://doi.org/10.1007/978-1-4939-9164-8_17
Bombaci M, Rossi RL. Computation and selection of optimal biomarker combinations by integrative ROC analysis using CombiROC. Methods Mol Biol 2019; 1959: 247–59. https://doi.org/10.1007/978-1-4939-9164-8_16
El-Khoury V, Schritz A, Kim S-Y, et al. Identification of a blood-based protein biomarker panel for lung cancer detection. Cancers (Basel) 2020; 12: 1629. https://doi.org/10.3390/cancers12061629
Vizza E, Cutillo G, Bruno V, et al. Pattern of recurrence in patients with endometrial cancer: A retrospective study. Eur J Surg Oncol 2020; 46: 1697–702. https://doi.org/10.1016/j.ejso.2020.03.203
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12–39. https://doi.org/10.1136/ijgc-2020-002230
Santacana M, Maiques O, Valls J, et al. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. Hum Pathol 2014; 45: 2394–403. https://doi.org/10.1016/j.humpath.2014.06.031
Buchynska LG, Iurchenko NP, Verko NP, et al. FOXP3 gene promoter methylation in tumor cells of endometrial cancer patients. Exp Оncol 2015; 37: 246–49.
Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet 2016; 387: 1094–108. https://doi.org/10.1016/ S0140-6736(15)00130-0
Nyen TV, Moiola CP, Colas E, et al. Modeling endometrial cancer: past, present, and future. Int J Mol Sci 2018; 19: 2348. https://doi.org/10.3390/ijms19082348
Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018; 29: 1180–8. https://doi.org/10.1093/annonc/mdy058
Martinez-Garcia E, Lopez-Gil C, Campoy I, et al. Advances in endometrial cancer protein biomarkers for use in the clinic. Expert Rev Proteomics 2018; 15: 81–99. https://doi.org/10.1080/14789450.2018.1410061
Rabban JT, Gilks CB, Malpica A, et al. Issues in the differential diagnosis of uterine low-grade endometrioid carcinoma, including mixed endometrial carcinomas: Recommendations from the International Society of Gynecological Pathologists. Int J Gynecol Pathol 2019; 38: S25–39. https://doi.org/10.1097/PGP.0000000000000512
Carlson JW, Nastic D. High-grade endometrial carcinomas: classification with molecular insights. Surg Pathol Clin 2019; 12: 343–62. https://doi.org/10.1016/j.path.2019.02.003
Brieieva OV, Nesina IP, Iurchenko NP, Buchynska LG. Peculiarities of c-Myc protein expression in endometrial carcinomas with signs of an aggressive course of the disease. Oncologiya 2019; 21: 304–9 (in Ukrainian).
Coll-de la Rubia E, Martinez-Garcia E, Dittmar G, et al. Prognostic biomarkers in endometrial cancer: a systematic review and meta-analysis. J Clin Med 2020; 9: 1900. https://doi.org/10.3390/jcm9061900
Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015; 113: 299–310. https://doi.org/10.1038/bjc.2015.190
Willvonseder B, Stögbauer F, Steiger K, et al. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations. Cancer Immunol Immunother 2021; 70: 1679–89. https://doi.org/10.1007/s00262-020-02813-3
Newton P, Mason J, Hurt B, et al. Entropy, complexity and Markov diagrams for random walk cancer models. Sci Rep 2014; 4: 7558. https://doi.org/10.1038/srep07558
Buchynska LG, Glushchenko NM, Nesina IP, et al. Molecular phenotype of high-grade endometrioid carcinoma of the endometrium. Exp Oncol 2020; 42: 300–5.
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67–73. https://doi.org/10.1038/nature12113
Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet 2016; 387: 1094–108. https://doi.org/10.1016/ S0140-6736(15)00130-0
Obata T, Nakamura M, Mizumoto Y, et al. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma. PLoS One 2017; 12: e0188641. https://doi.org/10.1371/journal.pone.0188641
Baniak N, Gilks CB, DeCoteau J, Kinloch M. Diagnostic variation in p53 usage for endometrial carcinoma diagnosis: implications for molecular subtyping. Int J Gynecol Pathol 2020; 39: 514–21. https://doi.org/10.1097/PGP.0000000000000638
Kastenhuber ER, Lowe SW. Putting p53 in context. Cell 2017; 170: 1062–78. https://doi.org/10.1016/j.cell.2017.08.028
Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res 2021; 49: D605–12. https://doi.org/10.1093/nar/gkaa1074
Conte F, Fiscon G, Licursi V, et al. A paradigm shift in medicine: A comprehensive review of network-based approaches. Biochim Biophys Acta Gene Regul Mech 2020; 1863: 194416. https://doi.org/10.1016/j.bbagrm.2019.194416
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
